PressDECENTRALIZED TRIALS & RESEARCH ALLIANCE (DTRA) ANNOUNCES PRIORITIES AND INITIAL INITIATIVESGlobal Coalition Defines Initiatives to Accelerate the Adoption of Decentralized Research and Improve Access for ParticipantsMAY 17, 2021 – The Decentralized Trials & Research Alliance (DTRA) today announced its priorities and initial initiatives designed to realize the full potential of decentralized research to improve access and participation to make clinical trials more efficient, accessible and equitable. With more than 100 Member Organizations, DTRA is the leading multi-stakeholder initiative focused on accelerating the global adoption of decentralized research. DTRA members have defined four priority areas as a framework for new initiatives: 1. To establish common nomenclature & definitions, archetypes and key performance indicators around the practice of decentralized research. A full listing of the initiatives grouped by priority area is available here. While each priority area has several associated initiatives, the following have been prioritized in the immediate term: • Create a comprehensive Decentralized Research Glossary that is easily accessible to relevant stakeholders to establish common nomenclature and definitions including defining archetypes of decentralized trials. Over 100 DTRA Member Organizations are engaged in advancing policies, research practices and technologies that will accelerate the global adoption of patient-focused, inclusive, decentralized clinical trials and research. Members include life-sciences research companies and patient advocacy organizations; technology and service providers; and leading regulatory authorities, such as the U.S. Food and Drug Administration. Organizations interested in becoming alliance members can visit DTRA.org. ABOUT DTRA: DECENTRALIZED TRIALS & RESEARCH ALLIANCE (DTRA) REACHES MILESTONE OF 100 MEMBER ORGANIZATIONSGrowth of Global Industry Alliance Advances Mission to Increase Access to Clinical Trials and ResearchApril 26, 2021 (GLOBE NEWSWIRE) — The Decentralized Trials & Research Alliance (DTRA) today announced that it now counts more than 100 member organizations united in the shared mission to make clinical-trial participation widely accessible to patients. DTRA is the largest and only multi-stakeholder initiative focused on the global adoption of decentralized research methodology.
DECENTRALIZED TRIALS & RESEARCH ALLIANCE (DTRA) LAUNCHES TO DEMOCRATIZE AND ACCELERATE CLINICAL TRIALSNew Global Industry Coalition Aims to Dramatically Increase Access for All Patient Populations in Clinical Trials and ResearchDecember 10, 2020 – An historic alliance of life sciences and healthcare organizations seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The Decentralized Trials & Research Alliance (DTRA) plans to unite stakeholders, including healthcare companies, regulators, patient groups and research organizations, with a mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research. “The benefits of decentralized research methodologies have been apparent for some time, but adoption has been slow due to many factors including culture and the lack of a forum for stakeholders to collaborate.”, said Amir Kalali, MD, life science executive, founder of several collaborative life science communities, and co-convenor of DTRA. “The COVID-19 pandemic has forced organizations to adopt decentralized methodologies which have the potential to broadly accelerate drug development.” Experts estimate that COVID-19 may set back non-pandemic clinical trials by several years due to prospective patients’ inability or reluctance to schedule visits at physical research locations. Decentralized approaches to conducting research facilitate participation by a more diverse patient population and could ease COVID-19-imposed difficulties for both patients and clinical investigators. Inclusion of representative patient populations in clinical trials by race, age, and geographic location has long been an operational challenge. COVID-19 has amplified the disparities and inclusion biases that have become hurdles for potential trial participants. “Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives,” said Craig Lipset, DTRA co-convener, clinical innovation advisor, and a pioneer in decentralized trials. “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders we can remove remaining barriers to adopting new policies and practices that can impact patients today.” “Equal access to clinical trials is the foundation of Stand Up To Cancer’s Health Equity Initiative and supports our mission to make every cancer patient a long-term survivor,” said Sung Poblete, CEO of Stand Up To Cancer. “SU2C and DTRA’s efforts are aligned in the goal of making it possible for any patient, anywhere, to access trials with convenience and safety, during the pandemic and beyond.” DTRA Member organizations will provide expertise to identify and address gaps and needs and advance best practices through effective education and communication. Organizations interested in taking part can visit DTRA.org ABOUT DTRA: The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information. |